


## Information for Patients and Healthcare Professionals:

 **Imnovid® (pomalidomide) is structurally related to thalidomide and is expected to cause severe birth defects or death to an unborn baby therefore:**

- Women of childbearing potential must always use effective contraception.
- Women of childbearing potential must have pregnancy tests prior to starting treatment and every 4 weeks, prior to each prescription, to ensure that they are not pregnant, except in the case of confirmed tubal sterilisation.
- Male patients with pregnant partners or partners of childbearing potential not using effective contraception must always use condoms (even if man has had a vasectomy).
- If a female patient or female partner of a male patient suspects they are pregnant, they must contact their prescriber immediately.
- You **MUST** tell your prescriber immediately if you experience any symptom that causes concern.

For complete information on the side effects of pomalidomide, patients should read the Package Leaflet and HCPs should read the Summary of Product Characteristics.

## Information for Healthcare Professionals:

### Prescription Details:

Has the patient received counselling?	<input type="checkbox"/> Yes <input type="checkbox"/> No
Childbearing potential assessment	<input type="checkbox"/> WCBP* <input type="checkbox"/> WNCBP+ <input type="checkbox"/> Male
If the patient is a WCBP is she using effective contraception?	<input type="checkbox"/> Yes <input type="checkbox"/> No
If the patient is male, is he using condoms, if required?	<input type="checkbox"/> Yes <input type="checkbox"/> No

A completed Prescription Authorisation Form must accompany each prescription to confirm that the patient continues to use effective contraception (if required) and, in the case of a WCBP, is having a pregnancy test every 4 weeks before each prescription to ensure they are not pregnant.

\* Woman of childbearing potential

+ Woman of non-childbearing potential

## Information for Healthcare Professionals:

### Prescription Details:

This patient is receiving pomalidomide for the treatment of:

## Emergency Contact Information:

Emergency Prescriber Contact:

Telephone number during office hours:

Telephone number after office hours:

Further information is available in the Patient guide.



This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.